Insider · CIK 0001948238
Dana Pizzuti
officer
Files at CRNX (Crinetics Pharmaceuticals, Inc.). First filing Jan 7, 2025, latest Mar 21, 2025.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 3
$0 bought, $1.1M sold
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 19Weak | Crinetics Pharmaceuticals, Inc. | $86k 2,515 shares | -3% | - | |
| 0Weak | Crinetics Pharmaceuticals, Inc. | $195k 5,000 shares | -14% | - | |
| 12Weak | Crinetics Pharmaceuticals, Inc. | $781k 15,000 shares | -34% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 19, 2025 | CRNX Crinetics Pharmaceuticals, Inc. | SOpen-market sale Common Stock10b5-1 | -2,388 | $34.17 | $82k | 72,360 | Mar 21, 2025 |
| Mar 19, 2025 | CRNX Crinetics Pharmaceuticals, Inc. | SOpen-market sale Common Stock10b5-1 | -127 | $34.83 | $4,423 | 72,233 | Mar 21, 2025 |
| Feb 20, 2025 | CRNX Crinetics Pharmaceuticals, Inc. | AGrant or award Common Stock | +43,000 | $0.00 | $0 | 74,748 | Feb 24, 2025 |
| Feb 20, 2025 | CRNX Crinetics Pharmaceuticals, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +65,000 | $0.00 | $0 | 65,000 | Feb 24, 2025 |
| Feb 3, 2025 | CRNX Crinetics Pharmaceuticals, Inc. | MOption exercise Common Stock10b5-1 | +5,000 | $16.89 | $84k | 36,748 | Feb 5, 2025 |
| Feb 3, 2025 | CRNX Crinetics Pharmaceuticals, Inc. | SOpen-market sale Common Stock10b5-1 | -5,000 | $39.07 | $195k | 31,748 | Feb 5, 2025 |
| Feb 3, 2025 | CRNX Crinetics Pharmaceuticals, Inc. | MOption exercise Stock option (Right to Buy)derivative10b5-1 | -5,000 | $0.00 | $0 | 119,042 | Feb 5, 2025 |
| Jan 3, 2025 | CRNX Crinetics Pharmaceuticals, Inc. | MOption exercise Common Stock10b5-1 | +15,000 | $16.89 | $253k | 44,248 | Jan 7, 2025 |
| Jan 3, 2025 | CRNX Crinetics Pharmaceuticals, Inc. | SOpen-market sale Common Stock10b5-1 | -15,000 | $52.09 | $781k | 29,248 | Jan 7, 2025 |
| Jan 7, 2025 | CRNX Crinetics Pharmaceuticals, Inc. | MOption exercise Common Stock10b5-1 | +2,500 | $19.64 | $49k | 31,748 | Jan 7, 2025 |
| Jan 3, 2025 | CRNX Crinetics Pharmaceuticals, Inc. | MOption exercise Stock option (Right to Buy)derivative10b5-1 | -15,000 | $0.00 | $0 | 124,042 | Jan 7, 2025 |
| Jan 7, 2025 | CRNX Crinetics Pharmaceuticals, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -2,500 | $0.00 | $0 | 18,500 | Jan 7, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.